Precision BioSciences und Servier erweitern ihre Zusammenarbeit in der CAR-T-Entwicklung im Bereich Onkologie mit vier neuen Programmen, die auf hämatologische und solide Tumore abzielen

NEXT STORY
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
PREV STORY
Le baricitinib en association avec le remdésivir réduit le temps de guérison chez les patients hospitalisés atteints de la COVID-19 et participant à l’étude ACTT-2 commanditée par le NIAID
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial

BEVERLY, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), ...

author_avatar
NASDAQ Market News

Worldwide Active Pharmaceutical Ingredient Industry to 2027 – by Product Type, Form, Manufacturer Type, Application and Region

author_avatar
NASDAQ Market News

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™

author_avatar
NASDAQ Market News